Navigation Links
Study: Pulmatrix's PUR1900 Inhaled Cystic Fibrosis Drug Demonstrates High Lung Retention and Potency Against Fungal Infection
Date:10/8/2015

LEXINGTON, Mass., Oct. 8, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for cystic fibrosis, was active and potent in vitro against Aspergillus fumigatus, a pathogen causing pulmonary infection in cystic fibrosis, while achieving high lung concentrations and low systemic exposure in rats. The data will be presented today at the 2015 North American Cystic Fibrosis Conference in Phoenix, Ariz.

PUR1900 is formulated with Pulmatrix's proprietary iSPERSE™ (Inhaled Small Particles Easily Respirable and Emitted) dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects.

Researchers compared the pharmacokinetics and potency of itraconazole against two other antifungal compounds -- amphotericin B and voriconazole -- following intratracheal instillation in rats at doses of up to 1.5 mg/kg. Lung and plasma samples were collected beginning five minutes after instillation for seven to fourteen days. In vitro susceptibility testing was performed using broth microdilution testing against A. fumigatus, as well as A. niger, A. flavus, and 10 to 20 strains of Candida spp.

In rat pharmacokinetic studies, itraconazole showed a long duration of lung retention, with some clearance over a one week period. Subsequent studies with PUR1900 dry powder demonstrated that PUR1900 maintains high concentrations of itraconazole in both lung tissue and in bronchoalevolar lavage samples. Amphotericin B lung concentrations remained constant over one week, while voriconazole was rapidly absorbed and cleared from the lungs.  Most notably, the percentage of administered drug recovered in lung tissue for itraconazole was significantly higher than for amphotericin or voriconazole, and itraconazole had a long lung half-life, which may lead to less frequent dosing in the clinic. All three compounds exhibited potent activity against A.fumigatus in vitro.

"The pharmacokinetics and potency of PUR1900 demonstrate that the drug is likely to achieve the high local concentrations needed to combat fungal infections caused by Aspergillus spp while overcoming oral bioavailability limitations and minimizing systemic side effects such as drug interactions," said David L. Hava, PhD, Pulmatrix's chief scientific officer.

Dr. Richard Moss, emeritus professor of pediatrics at Stanford University, said: "Use of new technologies such as iSPERSE™ to deliver high concentrations of inhaled antifungal drugs directly to the lung have the potential to effectively prevent or treat serious fungal infections or allergies while avoiding problems of toxicities or resistance encountered with systemic use of oral or parenteral antifungals."
Link to Abstract: http://onlinelibrary.wiley.com/doi/10.1002/ppul.23297/full - Poster #393

The 29th Annual North American Cystic Fibrosis Conference is a scientific meeting for medical professionals in the field of cystic fibrosis research and care. The conference is sponsored by The Cystic Fibrosis Foundation.

About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD).  Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

For more information, visit www.pulmatrix.com. Follow Pulmatrix on Twitter at https://twitter.com/pulmatrix_inc, and on StockTwits at http://stocktwits.com/pulmatrix.Investor ContactMedia ContactTom Baker

David Schull, Russo PartnersDirect: 617-532-0624

Direct: (858) 717-2310tbaker@pulmatrix.com

David.Schull@russopartnersllc.com

 

 


'/>"/>
SOURCE Pulmatrix, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study: Pharmaceutical Government Affairs & Public Policy Groups Role in Supporting the Patient Journey
2. Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data
3. Precision Advisors Digital Trends Study: Pharmas Use of Tablets With Payers Growing in Use But Effectiveness Lags
4. UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs
5. Diovan Case Study: How to Become a Leader in a Crowded Marketplace
6. Study: 2015 Medicare Drug Plans Cover Fewer Drugs & Have More Restrictions
7. ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results
8. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
9. New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015
10. New Study: H.R. 4577 to Cost $21 Billion over 10 Years
11. New Study: Medicare Preferred Pharmacy Network Plans Offer Lower Average Premiums, Same Quality as Non-Preferred Network Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
Breaking Medicine Technology:
(Date:10/13/2017)... TX (PRWEB) , ... October 13, 2017 , ... ... planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, is ... boy fighting to overcome a rare and deadly chromosome abnormality. , After struggling ...
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
Breaking Medicine News(10 mins):